ライフサイエンスコーパス: oncologic

1 : With the Biograph Vision PET/CT system for oncologic (18)F-FDG imaging, scan duration or activity a

2 ated the effects of reduced scan duration in oncologic (18)F-FDG PET imaging on quantitative and subj

3 hm with an external, device-based system for oncologic (18)F-FDG PET/CT imaging.

4 essential elements of a concise and complete oncologic (18)F-FDG PET/CT report and illustrates these

5 pretation rather than underinterpretation of oncologic (18)F-FDG PET/CT studies prevails in clinical

6 to reduce the rates of misinterpretation of oncologic (18)F-FDG PET/CT studies.

7 their experience with the interpretation of oncologic (18)F-FDG PET/CT studies.

8 ation from physicians referring patients for oncologic (18)F-FDG PET/CT.

9 from a patient population (total n = 20, all oncologic (18)F-FDG PET/MR) were selected, and the impac

10 of less perioperative blood transfusions for oncologic abdominal surgery was observed.

11 racy in the detection of various vascular or oncologic abnormalities.

12 cer patients confers virologic, hepatic, and oncologic advantages.

13 the TLR3 agonist poly(I:C) as a model immune-oncologic agent.

14 K) possess much promise for the treatment of oncologic and autoimmune indications.

15 on of the rectal specimen did not compromise oncologic and functional outcome after laparoscopic surg

16 Oncologic and functional outcomes were compared between

17 The oncologic and functional results are excellent with acce

18 Five-year cumulative incidence of oncologic and nononcologic mortality were compared using

19 ion of PVE and chemotherapy may enhance both oncologic and operative safety.

20 ommunication, it presents many challenges in oncologic and palliative care settings.

21 ance (MR) imaging has been evaluated in many oncologic and rheumatologic indications and is emerging

22 Therapies targeting oncologic and vascular endothelial growth factor (VEGF)

23 ial as a life-saving treatment of monogenic, oncologic, and infectious diseases.

24 tential targets for metabolic, inflammatory, oncologic, and neurodegenerative disorders.

25 ies, including autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases, and id

26 vely used for disease activity evaluation in oncologic animal models, and we demonstrate their transl

27 Oncologic anthropology represents a transdisciplinary fi

28 Although the initial oncologic applications for tumor detection and character

29 to outline the potential value of PET/MRI in oncologic applications for which data on PET/MRI are sti

30 gnostic) purposes is a promising approach in oncologic applications.

31 ure of pancreatic ductal adenocarcinoma, the oncologic benefit of achieving a histologically complete

32 h intrahepatic cholangiocarcinoma (ICC), the oncologic benefit of surgery and perioperative outcomes

33 It is unclear whether PSH confers an oncologic benefit through increased salvageability or is

34 Purpose Despite documented oncologic benefit, use of postoperative adjuvant radioth

35 ery for malignancies is to achieve a maximum oncologic benefit.The relevance of the laparoscopic appr

36 h postoperative mortality rate and uncertain oncologic benefits have limited the use of P-AR for loca

37 e regularly pointed out regarding safety and oncologic benefits.

38 ces (e.g. viral infection, overnutrition, or oncologic burden) is a global health problem.

39 this novel technology; and present potential oncologic, cardiac, and neuropsychiatric applications.

40 Systemic oncologic care can continue without interruption.

41 e association between hospital TVP category, oncologic care processes, and perioperative outcomes.

42 tween these volume thresholds and quality of oncologic care.

43 ers within the bone marrow remains a crucial oncologic challenge due to issues of drug availability a

44 to those in adults they represent a complex oncologic challenge.

45 ients who presented to an integrated dermato-oncologic clinic in a tertiary referral medical center w

46 al of 310 consecutive patients who underwent oncologic colorectal surgery were included in a prospect

47 and 17 years and were diagnosed as having an oncologic condition 1 month to 1 year before enrollment.

48 point inhibitors are now frequently used for oncologic conditions.

49 hemical, histologic, and imaging measures of oncologic control.

50 hospitalized children with critical illness, oncologic diagnoses, or transplants.

51 rity of illness at ICU admission, and active oncologic diagnosis were the other independent predictor

52 onutrition should be prescribed before major oncologic digestive surgery to decrease postoperative mo

53 perative use of immunonutrition before major oncologic digestive surgery was not associated with any

54 licated in a broad range of inflammatory and oncologic diseases.

55 toinflammatory diseases, and hematologic and oncologic disorders, giving rise to a new class of drugs

56 say has also emerged as an important tool in oncologic drug design programs for targeting RAD51.

57 n tumor cell lines, RI-1 holds promise as an oncologic drug.

58 aging phase II results, the vast minority of oncologic drugs in development receive regulatory approv

59 eetings at which votes were cast relating to oncologic drugs.

60 omplexity and technique on early and midterm oncologic efficacy and rate of complications for 100 con

61 erm follow-up is needed to establish durable oncologic efficacy and survival relative to competing ab

62 The short-term oncologic efficacy of endoscopic resection (ER) and abla

63 evel of evidence in addressing the long-term oncologic efficacy of laparoscopic versus open resection

64 The oncologic efficacy of MRI-guided FLA is currently being

65 for the treatment of invasive BCa before the oncologic efficacy of these techniques can be adequately

66 herapy for low-risk prostate cancer, and the oncologic efficacy of this treatment modality is current

67 nd efficiently, without negatively affecting oncologic efficacy or long-term survival, when compared

68 r clinical trials are necessary to establish oncologic efficacy.

69 py (EBRT) have been shown to improve various oncologic end points.

70 ded to other contemporary work that suggests oncologic equivalence and renal functional benefit compa

71 T2N0 cancer (OC), but, to our knowledge, the oncologic equivalence of SN biopsy and neck lymph node d

72 This study demonstrated the oncologic equivalence of the SN and ND approaches, with

73 ents derive benefit from LH and to determine oncologic equivalence to OH.

74 ing surgery over radical nephrectomy and its oncologic equivalency confirmed, there is an increased p

75 d deviation]; six men) referred for a PET/CT oncologic examination who had undergone imaging between

76 his observational single-center study, 1,003 oncologic examinations (918 patients; mean age, 57.8 +/-

77 Extensive oncologic experience argues that the most efficacious ap

78 e rigorous definitions that account for both oncologic factors and geriatric domains.

79 s (M/F: 1.4; mean age 63 years) attended the oncologic follow-up (mean 24 months) and were found dise

80 Life-long oncologic follow-up is crucial for all retinoblastoma su

81 Metabolic and oncologic follow-up is presented.

82 Oncologic follow-up of patients in group B is in progres

83 Despite close oncologic follow-up, a biopsy, positron emission tomogra

84 e surgery for a potential application in the oncologic follow-up.

85 performed using what we called a peri-rectal oncologic gateway for retroperitoneal endoscopic single

86 retrieval rate that met or exceeded current oncologic guidelines and published benchmarks, and a fav

87 PET/CT has become the reference standard in oncologic imaging against which the performance of other

88 tastases and should be considered for future oncologic imaging clinical trials.

89 In animal models of cancer, oncologic imaging has evolved from a simple assessment o

90 scope of DWI has since broadened to include oncologic imaging of the prostate gland, breast, and liv

91 agents and highlights the current status of oncologic imaging with radiolabeled AAs in terms of trac

92 nical work flow in the form of (18)F-FDG for oncologic imaging, with reliable daily production and di

93 al respiratory gating (ORG)-as developed for oncologic imaging-using a narrow range of breathing ampl

94 ransport, a relatively unexplored target for oncologic imaging.

95 F-FDG PET/CT or (131)I SPECT/CT for standard oncologic indications at our institution in Brescia, Ita

96 related to bone-modifying agents (BMAs) for oncologic indications published between January 2009 and

97 gents that are clinically approved for other oncologic indications, agents in active clinical develop

98 Group 1 included oncologic indications, and groups 2 and 3 infection or i

99 een implicated in mediating inflammatory and oncologic indications, their roles in lung fibrosis have

100 warranted to evaluate its clinical value in oncologic indications.

101 ], indication for (18)F-FDG PET/CT scanning [oncologic, infection/inflammation, or miscellaneous], ty

102 The oncologic inferiority of the APE technique in comparison

103 astases may be conceptualized as progressive oncologic injury to the nervous system.

104 carcinoma (RCC) has been at the forefront of oncologic innovation.

105 zed controlled trials that compared a psycho-oncologic intervention delivered face-to face with a con

106 Various types of psycho-oncologic interventions are associated with significant,

107 tudy aimed to evaluate the effects of psycho-oncologic interventions on emotional distress and qualit

108 Cancer surgeons should continue to use their oncologic knowledge to determine the window of opportuni

109 ificantly improve neurosurgical resection of oncologic lesions through improved differentiation betwe

110 tients) referred for staging or restaging of oncologic malignancies underwent whole-body imaging with

111 or ARGX-111 clinical testing in MET-positive oncologic malignancies.

112 odal involvement, and metastatic disease) or oncologic management changes were recorded.

113 Changes in oncologic management occurred in 7 patients.

114 Somatostatin analogues are the mainstay of oncologic management of bowel NETs; everolimus, streptoz

115 For oncologic management or radiotherapy planning, reliable

116 ith TNM staging based on ceCT and changes in oncologic management were recorded.

117 a patient's spine disease: NOMS (neurologic, oncologic, mechanical instability, and systemic disease)

118 lly in presentation and behavior, reflecting oncologic mechanisms unique to each.

119 uded electronic databases and proceedings of oncologic meetings.

120 eed to develop and apply clinically relevant oncologic models that are amenable to available patient

121 The cumulative incidence of oncologic mortality was not significantly different betw

122 The patients were referred for oncologic (n = 10), infectious/inflammatory (n = 5), and

123 ls were significantly more likely to address oncologic (NIH = 15.5%, Other = 3%, Industry = 1.5%; P <

124 ing caused a high, medium, and low change in oncologic or radiooncologic management in 19%, 33%, and

125 hanges in tumor stage or localization and in oncologic or radiooncologic management were recorded.

126 eading to relevant changes in TNM status and oncologic or radiooncologic management.

127 Studies of critically ill, oncologic or stem cell transplant, and solid organ trans

128 pressive treatment has not led to metabolic, oncologic, or infectious complications.

129 However, the oncologic outcome appears equivalent to cases without ma

130 For perioperative and oncologic outcome comparison, contemporary OE controls w

131 e mortality, but achieve appealing long-term oncologic outcome especially those with favorable tumor

132 roves tumor staging and leads to a favorable oncologic outcome in patients with localized ACC.

133 Purpose To evaluate urogenital toxicity and oncologic outcome of MRI-transrectal US fusion-guided IR

134 The association between classification and oncologic outcome was determined using an additional, in

135 improved pCR in group B translates to better oncologic outcome.

136 orm a complete analysis of the predictors of oncologic outcome.

137 leak, blood loss, reoperation, readmission, oncologic outcomes (R0-resection, lymph nodes harvested)

138 Compare oncologic outcomes after open and robotic pancreatic res

139 RAMIE can be performed safely with excellent oncologic outcomes and decreased hospital stay when comp

140 tomy in a high-volume experienced center for oncologic outcomes and due to decreased blood loss and t

141 aim of developing a method to assess risk of oncologic outcomes and guide management decisions for bo

142 dies of cost, quality of life, and long-term oncologic outcomes are needed.

143 , their surgical outcomes reported but their oncologic outcomes are still pending.

144 PPH, bile leak, reoperation, readmission, or oncologic outcomes between LPD and OPD.

145 randomized studies, this study compared the oncologic outcomes between patients treated with RC or T

146 We compared short-term oncologic outcomes between rectal cancer patients underg

147 s demonstrating noninferiority for long-term oncologic outcomes between the 2 approaches.

148 robotic LAR is not associated with superior oncologic outcomes compared to laparoscopic LAR.

149 erall survival; short-term perioperative and oncologic outcomes encompassing margin positivity, perma

150 hemoradiation for esophageal cancer improves oncologic outcomes for a broad group of patients with lo

151 Improved oncologic outcomes for esophageal cancer have resulted i

152 nd advanced cancer stage are associated with oncologic outcomes for numerous common cancers.

153 ss assessed by CT imaging or BMI can predict oncologic outcomes for patients with HNSCC, whereas weig

154 combining IMI with PET may provide superior oncologic outcomes for patients with resectable lung can

155 The negative impact of POC on oncologic outcomes has been reported in various types of

156 With improved oncologic outcomes in esophageal cancer, there is an inc

157 s 30-day mortality, and short- and long-term oncologic outcomes in esophageal cancer.

158 a critical driver of treatment response and oncologic outcomes in OPSCC generally and HPV+ OPSCC mor

159 at have been shown to improve functional and oncologic outcomes in randomized clinical trials.

160 eatment modalities hold promise of improving oncologic outcomes in the future.

161 hing is an independent predictor of improved oncologic outcomes including survival.

162 ong men with very low-risk PCa, we evaluated oncologic outcomes of AA men with very low-risk PCa who

163 The long-term oncologic outcomes of laparoscopic gastrectomy for patie

164 e study was to compare the postoperative and oncologic outcomes of laparoscopic versus open surgery f

165 The oncologic outcomes of laparoscopy-assisted gastrectomy f

166 imary objective was to determine the 10-year oncologic outcomes of PCA for stage I RCC in a prospecti

167 coma surgery; however, the perioperative and oncologic outcomes of this strategy are not well describ

168 endotherapy, but alimentary satisfaction and oncologic outcomes support esophageal preservation with

169 Consequently, differences in oncologic outcomes that were observed in population-base

170 able approach for CRLM patients with similar oncologic outcomes to anatomical resections, this may no

171 in most academic institutions, with similar oncologic outcomes to radical nephrectomy.

172 act on in-hospital mortality and longer-term oncologic outcomes were analyzed in retrospective cohort

173 s were discovered in 27.6% of pCND patients, oncologic outcomes were comparable at 1 year.

174 Early postoperative and oncologic outcomes were evaluated.

175 s that suggest that VATS does not compromise oncologic outcomes when used for early-stage lung cancer

176 In order to achieve excellent functional and oncologic outcomes with minimal perioperative complicati

177 ted results comparable to open techniques in oncologic outcomes with regard to the number of lymph no

178 atory state is thought to be associated with oncologic outcomes, and NLR has been used as a simple an

179 Pending clinical oncologic outcomes, the findings do not support the use

180 PD for cancer have equivalent short-term and oncologic outcomes, when compared with patients who unde

181 re is equivalent to open resection regarding oncologic outcomes.

182 ificant differences were found in short-term oncologic outcomes.

183 tive morbidity and possibly poorer long-term oncologic outcomes.

184 pendent predictors of LTP and yield the best oncologic outcomes.

185 erioperative opioid exposure and longer term oncologic outcomes.

186 hologic Gleason score seem to present better oncologic outcomes.

187 For most, it resolves, with no impact on oncologic outcomes.

188 t the time of radical cystectomy to optimize oncologic outcomes.

189 ss of visualization leading to compromise in oncologic outcomes.

190 adverse pathologic features at RP and poorer oncologic outcomes.

191 endently predictive factors of pneumonia and oncologic outcomes.

192 d with low urogenital toxicity and promising oncologic outcomes.

193 sess its independent impact on operative and oncologic outcomes.

194 urgical infection is associated with adverse oncologic outcomes; however, the mechanisms underlying t

195 The new oncologic paradigm of precision medicine is focused on i

196 us in cancer surgery represents an important oncologic parameter affecting overall prognosis.

197 ssociated with metabolic, cardiovascular and oncologic pathophysiology.

198 Improved knowledge of tumor genetics and oncologic pathways has contributed to a better understan

199 logy has emerged as an integral component of oncologic patient care, committed to the early diagnosis

200 Sixty-four oncologic patients (14 men and 50 women; mean age, 65.3

201 Results: In total, 30 oncologic patients (22 men, 8 women; age: 48-88 y [range

202 Fifty-one oncologic patients (mean age +/- SD, 56.6 +/- 14.0 y; 29

203 PET/CT, qualitatively and quantitatively, in oncologic patients and assess the confidence and degree

204 mprove diagnostic performance, especially in oncologic patients in certain indications.

205 Methods: In total, 20 oncologic patients were enrolled and received a single 3

206 Thirty-eight oncologic patients who underwent FDG PET/unenhanced mult

207 In 121 oncologic patients with 241 lung lesions, PET/MRI was pe

208 After ethics approval, in 8 oncologic patients with dental implants data were acquir

209 r, lung metastases are a frequent finding in oncologic patients, and for imaging of the lung CT is st

210 Twenty-one oncologic patients, mean age 58 y, first underwent clini

211 In a series of oncologic patients, vascular uptake of (68)Ga-DOTATOC an

212 with FDG PET/unenhanced multidetector CT in oncologic patients.

213 detecting and characterizing lung lesions in oncologic patients.

214 Current oncologic PDAC therapies confer marginal benefit and, th

215 s may be suitable for further development as oncologic PET imaging agents.

216 The National Oncologic PET Registry (NOPR) collected data on intended

217 The National Oncologic PET Registry (NOPR) developed a NaF PET regist

218 beneficiaries participating in the National Oncologic PET Registry (NOPR).

219 ked post-NaF PET data of consenting National Oncologic PET Registry participants age 65 y or older fr

220 The National Oncologic PET Registry prospectively assessed the impact

221 ypes of cancer participating in the National Oncologic PET Registry.

222 ol values from sites that conduct whole-body oncologic PET/CT examinations and participated in the sc

223 Pediatric oncologic PET/MR is technically feasible, showing satisf

224 nce is recommended as a routine protocol for oncologic PET/MR.

225 pecific information relevant to surgical and oncologic planning.

226 in less-selected patients treated in general oncologic practice.

227 h reduction mammoplasty could provide a safe oncologic procedure with immediate breast reconstruction

228 k stratification, functional assessment, and oncologic prognostication, elderly patients with cancer

229 tion of somatostatin receptor subtype 2, for oncologic purposes, is frequently made using the DOTA-de

230 e relationship for morbidity, mortality, and oncologic quality has been reported for OPD, comparative

231 Oncologic reading was performed first according to PERCI

232 ctive and subjective image parameters and on oncologic readings in whole-body (18)F-FDG PET/MRI.

233 ization of minimally invasive techniques for oncologic rectal resections.

234 PET/CT systems, especially in neurologic and oncologic research.

235 gional lymph nodes (MRLN) precludes curative oncologic resection or liver transplantation for cholang

236 suring both parenchymal sparing and suitable oncologic resection.

237 hort does not experience poor outcomes after oncologic resection.

238 least 18 months after esophageal or gastric oncologic resections represented the study cohort.

239 after T-NACT is, in part, unrelated to their oncologic response.

240 t-term outcomes and pathologic surrogates of oncologic results among patients undergoing robotic vers

241 The oncologic results are promising, with low positive margi

242 These patients exhibited oncologic results comparable to those of patients with n

243 Long-term oncologic results, however, are lacking.

244 ble short-term outcomes without compromising oncologic results.

245 agents to the therapeutic armamentarium for oncologic, rheumatologic, and neurologic disorders has r

246 risk PCa should be counseled about increased oncologic risk when deciding among their disease managem

247 was designed using evidence-based facts and oncologic rules: laparoscopy with pneumoperitoneum, low

248 er, its impact on outcomes, particularly its oncologic safety for tumors greater than 5 cm, remains u

249 increased in popularity due to its perceived oncologic safety in many women and to reports of superio

250 of more than 10 years confirms the long-term oncologic safety of laparoscopic surgery for rectal canc

251 ed clinical trials (RCTs) have evaluated the oncologic safety of laparoscopic versus open surgery for

252 These findings question the oncologic safety of laparoscopy for the treatment of rec

253 surgery, no high-level evidence supports the oncologic safety of this approach.

254 gh few have been explicitly validated in the oncologic setting.

255 omagenesis and its optimal management in the oncologic setting.

256 for clinical evaluation in a broad number of oncologic settings where mTOR signaling has a pathogenic

257 ted theranostics in preclinical and clinical oncologic settings.

258 regulatory approvals are expected across the oncologic spectrum for a variety of other agents that ta

259 ation of patient residence, comorbidity, and oncologic stage.

260 With oncologic studies being the primary application of PET,

261 Initial oncologic studies show that the aptamer inhibits cell in

262 st-line of treatment for patients undergoing oncologic surgeries.

263 s guiding discharge opioid prescriptions for oncologic surgery are lacking, and factors driving presc

264 Achieving cancer-free surgical margins in oncologic surgery is critical to reduce the need for add

265 Mortality after complex oncologic surgery is highly variable across hospitals, a

266 assess surgical margins in real-time during oncologic surgery leads to incomplete tumor removal, inc

267 on is prescribed systematically before major oncologic surgery to treat a potential malnutrition acco

268 r conversions to open, surrogates for proper oncologic surgery were nearly identical between the 2 ap

269 r conversions to open, surrogates for proper oncologic surgery were nearly identical between the 2 ap

270 nge, 34-95 years), underwent major abdominal oncologic surgery with an indwelling EC.

271 ecialties included bariatric surgery, breast oncologic surgery, orthopedic surgery, plastic and recon

272 ty of venous thromboembolism (VTE) following oncologic surgery.

273 e critical importance of improving access to oncologic surgical care internationally.

274 ks of postoperative mortality and suboptimal oncologic surgical quality following PD are higher in lo

275 hed less than 113 kg and who were undergoing oncologic surveillance (from April 2017 to July 2018) an

276 Therefore, a variety of interventional oncologic techniques have been developed for treating se

277 Modern oncologic therapies and care have resulted in a growing

278 ngle- and multiple-center clinical trials of oncologic therapies by providing acceptable (minimum), t

279 ls to reveal resistance mechanisms to immuno-oncologic therapies caused by the immuno-metabolic inter

280 s prevalence has increased as more effective oncologic therapies have improved patient survival, but

281 ents that remain a barrier to current immuno-oncologic therapies in hepatocellular carcinoma.

282 erapeutic regimen, type of disease, previous oncologic therapies, clinical morphology of cutaneous le

283 inform susceptibility and response to immuno-oncologic therapies, providing a therapeutic strategy to

284 using an identical imaging protocol, with no oncologic therapy between sessions.

285 promising first-in-class compound to attempt oncologic therapy without cardiotoxicity, based on targe

286 ncreasing the effectiveness of a mainstay of oncologic therapy.

287 nt TC was tracked for 6 or more months after oncologic thyroidectomy.

288 h the diseases' longevity and an increase in oncologic transformation suggest a rising disease burden

289 Oncologic treatment and outcomes as well as clinical gen

290 cans were extracted from patients undergoing oncologic treatment from 2014 to 2017.

291 Success with oncologic treatment has allowed cancer patients to exper

292 herapy might be a favorable option for radio-oncologic treatment in this tumor type.

293 mor-associated antigens and provide a viable oncologic treatment option for solid tumors.

294 he use of (18)F-FDG PET/MRI for quantitative oncologic treatment response assessments.

295 and costly and, if unplanned, may interrupt oncologic treatment.

296 gate for overall survival (OS) in trials for oncologic treatments.

297 Oncologic variables, including number of resected lymph

298 CT in lesion detection and classification in oncologic whole-body examinations and to investigate rad

299 /MRI might be possible down to 2 MBq/kgBW in oncologic whole-body examinations.

300 These range from the inflammatory to the oncologic with an undisputed link to hepatitis, liver ci